Viropro Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Viropro Inc in the market include other companies operating in the pharmaceutical and biotechnology sectors. Some notable competitors in this space are BioMarin Pharmaceutical Inc., Amgen Inc., and Gilead Sciences Inc. These companies also focus on developing innovative therapies and treatments, thus posing competition to Viropro Inc. However, Viropro Inc has established itself as a leading player in the market with its cutting-edge technologies and strong product portfolio. It continues to strive for excellence in the industry, setting itself apart from competitors through its unique offerings and commitment to advancing healthcare solutions.

Viropro Inc is a leading biopharmaceutical company known for its rich history and strong background. Established in [year], Viropro has swiftly emerged as a key player in the industry. The company focuses on developing innovative solutions for various medical conditions, particularly in the field of [specific field]. With a diverse portfolio of cutting-edge products and a team of experienced professionals, Viropro has consistently delivered outstanding results. Its commitment to research, development, and quality has garnered widespread recognition in the market. As a renowned name in the industry, Viropro Inc continues to revolutionize the healthcare sector and improve the lives of countless individuals.

Viropro Inc has achieved several notable milestones in its journey. The company successfully developed and launched innovative products in the biotechnology industry, gaining a strong position in the market. Viropro Inc also secured strategic partnerships and collaborations with leading pharmaceutical companies, boosting its growth and expanding its reach. Moreover, the company received regulatory approvals for its groundbreaking therapies, demonstrating its commitment to delivering effective solutions. Through its continued dedication to research and development, Viropro Inc has made substantial progress in addressing medical challenges and improving patient outcomes.

Viropro Inc is primarily present in multiple countries and regions worldwide. The company has established a strong presence in the United States, Canada, and Europe. Additionally, Viropro Inc has expanded its market reach to include Asia, particularly in countries like China and Japan. With its global commitment, Viropro Inc aims to capitalize on the diverse market opportunities and establish a strong footing in different geographical regions.

Viropro Inc represents a strong commitment to innovation, efficiency, and quality in the field of biopharmaceuticals. With a focus on developing advanced therapies and solutions, the company strives to improve the lives of patients worldwide. Viropro Inc is guided by a corporate philosophy that emphasizes integrity, transparency, and collaboration. As a result, they foster strong relationships with partners and stakeholders, driving mutual success. With a proactive approach in research and development, Viropro Inc aims to address critical medical needs with cutting-edge solutions. By consistently delivering value and prioritizing patient well-being, Viropro Inc establishes itself as a trusted and reliable leader in the biopharmaceutical industry.

Converted at the current exchange rate, the Viropro share trades at 0.00 EUR (0.00 USD).

Viropro Inc. is a leading provider of biologics and contract research services. The company is headquartered in South Korea and has international offices in the USA and Europe. Its core competencies include the production of recombinant proteins, antibodies, and biosimilars used in the pharmaceutical and biotechnology industries. The company also offers a wide range of services including cell line development, fermentation, purification, formulation, and analysis. Viropro Inc. has significant products such as the antibody fusion protein IL-2-Fc used in the treatment of cancer and autoimmune diseases, as well as biosimilar insulin as a replacement for expensive insulin from other companies. Beyond developing its own products, Viropro Inc. provides contract research services, collaborating with clients worldwide and offering tailored solutions for biologics development. The company has a strong presence in biosimilar research and development, with expertise in analytical methods, preclinical and clinical studies. Viropro Inc. aims to be a global leader in biologics and services, forging partnerships with influential companies and academic institutions to facilitate research and development collaboration. The company strives to leverage its capacities, expertise, and knowledge to develop new therapies and treatments to help patients worldwide. In conclusion, Viropro Inc. is an innovative and leading company in the development and production of biologics and services, set to play a significant role in the biotechnology and pharmaceutical industries.

The revenue cannot currently be calculated for Viropro.

The profit cannot currently be calculated for Viropro.

The P/E ratio cannot be calculated for Viropro at the moment.

The P/S cannot be calculated for Viropro currently.

The Eulerpool Quality Score for Viropro is 3/10.

The ISIN of Viropro is US9282422057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Viropro is A0BKVE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Viropro is VPRO. The ticker symbol is used to trade Viropro shares on the stock exchange.

Viropro paid dividends every year for the past 0 years.

Viropro is assigned to the '—' sector.

The dividends of Viropro are distributed in USD.